S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:ELEV

Elevation Oncology - ELEV Price Target & Analyst Ratings

$0.93
+0.03 (+3.32%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.91
$1.03
50-Day Range
$0.89
$1.19
52-Week Range
$0.86
$7.50
Volume
16,910 shs
Average Volume
45,561 shs
Market Capitalization
$21.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.83

Elevation Oncology Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$5.83
524.15% Upside
High Prediction$8.00
Average Prediction$5.83
Low Prediction$2.00
TypeCurrent
12/2/21 to 12/2/22
1 Month Ago
11/2/21 to 11/2/22
3 Months Ago
9/3/21 to 9/3/22
1 Year Ago
12/2/20 to 12/2/21
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$5.83$7.75$10.00$20.78
Predicted Upside524.15% Upside554.01% Upside226.26% Upside71.69% Upside
Get Elevation Oncology Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.


ELEV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ELEV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Elevation Oncology Stock vs. The Competition

TypeElevation OncologyMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside524.15% Upside569.87% Upside11.38% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
11
52.38%
Underperform Votes
10
47.62%
Avg. Outperform Votes
164
66.40%
Avg. Underperform Votes
83
33.60%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/10/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight
11/7/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$11.00 ➝ $2.00+110.17%
9/19/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$7.50+557.89%
7/29/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Driscoll
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform$15.00 ➝ $8.00+550.40%
7/20/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$12.10
(Data available from 12/2/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ELEV Price Target - Frequently Asked Questions

What is Elevation Oncology's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Elevation Oncology stock is Hold based on the current 1 sell rating, 1 hold rating and 2 buy ratings for ELEV. The average twelve-month price prediction for Elevation Oncology is $5.83 with a high price target of $8.00 and a low price target of $2.00. Learn more on ELEV's analyst rating history.

Do Wall Street analysts like Elevation Oncology more than its competitors?

Analysts like Elevation Oncology less than other Medical companies. The consensus rating for Elevation Oncology is Hold while the average consensus rating for medical companies is Buy. Learn more on how ELEV compares to other companies.

Do MarketBeat users like Elevation Oncology more than its competitors?

MarketBeat users like Elevation Oncology less than other Medical companies. 52.38% of MarketBeat users gave Elevation Oncology an outperform vote while medical companies recieve an average of 66.40% outperform votes by MarketBeat users.

Is Elevation Oncology being downgraded by Wall Street analysts?

Over the previous 90 days, Elevation Oncology's stock had 2 downgrades by analysts.

Does Elevation Oncology's stock price have much upside?

According to analysts, Elevation Oncology's stock has a predicted upside of 426.85% based on their 12-month price targets.

What analysts cover Elevation Oncology?

Elevation Oncology has been rated by HC Wainwright, JPMorgan Chase & Co., and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ELEV) was last updated on 12/2/2022 by MarketBeat.com Staff